148 - Right to try act; Xeljanz for ulcerative colitis; Baricitinib for RA; first artificial iris; AURA™ ICP Monitoring System; neuro stent device; NKTR-181 first in class opioid; Priority Review for antiepileptic drug FYCOMPA® (perampanel); TX-004HR:

June 1, 2018 0:54 Statement from FDA Commissioner Scott Gottlieb, M.D., on the signing of the Right to Try Act 2:38 FDA approves new treatment for moderately to severely active ulcerative colitis 4:50 Baricitinib 2-mg tablets for the treatment of adults with moderately-to-severely active rheumatoid arthritis 6:12 FDA approves first artificial iris 8:10 510(k) clearance for AURA™ ICP Monitoring System 9:40 FDA Approval For Neuro Stent Device 11:05 NDA for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Low Back Pain in Adult Patients New to Opioid Therapy 12:30 Priority Review for antiepileptic drug FYCOMPA® (perampanel) CIII for pediatric patients 13:50 FDA Approval of TX-004HR: IMVEXXY™ (estradiol vaginal inserts), the Lowest Dose Vaginal Estrogen Product Approved for the Treatment of Moderate to Severe Dyspareunia, a Symptom of VVA, due to Menopause 14:50 clearance of IND application on CAR-T immuno-cell therapy for the Treatment of Multiple Myeloma 16:30 As part of efforts to combat opioid crisis, FDA launches innovation challenge to spur development of medical devices ‒ including digital health and diagnostics ‒ that target pain, addiction and diversion Music credit: freemusicarchive.org/music/MindsEye/Yellow_Taxi/

You can listen to 148 - Right to try act; Xeljanz for ulcerative colitis; Baricitinib for RA; first artificial iris; AURA™ ICP Monitoring System; neuro stent device; NKTR-181 first in class opioid; Priority Review for antiepileptic drug FYCOMPA® (perampanel); TX-004HR: online on Radio and Podcast. Open the player on this page to stream the available audio.

148 - Right to try act; Xeljanz for ulcerative colitis; Baricitinib for RA; first artificial iris; AURA™ ICP Monitoring System; neuro stent device; NKTR-181 first in class opioid; Priority Review for antiepileptic drug FYCOMPA® (perampanel); TX-004HR: is an episode from New FDA Approvals.

This episode is 19:20 long.

This episode was published on Jun 1, 2018.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from New FDA Approvals when more episodes are available from the podcast feed.